학술논문
BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1 2022.
Document Type
Article
Author
Source
Subject
*HIV infection transmission
*HIV infection epidemiology
*KIDNEY physiology
*COGNITION disorder risk factors
*HIV prevention
*HIV infections
*THERAPEUTICS
*HIV-positive persons
*PATIENT refusal of treatment
*CARDIOVASCULAR diseases risk factors
*CHRONIC kidney failure
*BONE diseases
*RALTEGRAVIR
*EFAVIRENZ
*AFFINITY groups
*SOCIAL support
*PATIENT participation
*COMBINATION drug therapy
*HIV integrase inhibitors
*ATAZANAVIR
*HEALTH services accessibility
*TRANSITION to adulthood
*VIRAL load
*PHARMACOLOGY
*ANTIRETROVIRAL agents
*MENTAL health
*WOMEN
*RILPIVIRINE
*MEDICAL care
*MEDICAL protocols
*TREATMENT failure
*METABOLIC disorders
*LIVER diseases
*RISK assessment
*DARUNAVIR
*LAMIVUDINE
*WEIGHT gain
*TREATMENT effectiveness
*COMMUNICATION
*DECISION making
*DRUGS
*AGING
*TERMS & phrases
*NON-nucleoside reverse transcriptase inhibitors
*RITONAVIR
*EMTRICITABINE-tenofovir
*DRUG interactions
*PSYCHOLOGY of women
*MEDICAL practice
*PROFESSIONAL associations
*TERMINATION of treatment
*DRUG resistance in microorganisms
*PATIENT compliance
*ABACAVIR
*EMTRICITABINE
*ENZYME inhibitors
*SEXUAL health
*REPRODUCTIVE health
*DISEASE risk factors
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
1464-2662
Abstract
The article presents guidelines given by the British HIV Association (BHIVA) on best clinical practice for antiretroviral therapy (ART) and management of adults living with human immunodeficiency virus (HIV). Topics discussed include involvement of people living with HIV, primary aim of ART, and considerations when managing people with spontaneous HIV viral control.